abiraterone has been researched along with niclosamide in 2 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (niclosamide) | Trials (niclosamide) | Recent Studies (post-2010) (niclosamide) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 979 | 19 | 465 |
| Protein | Taxonomy | abiraterone (IC50) | niclosamide (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 13.7 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 10 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.28 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 10 | |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 0.23 | |
| Anoctamin-1 | Homo sapiens (human) | 0.028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, C; Gao, AC; Liu, C; Lou, W; Zhu, Y | 1 |
| Agarwal, N; Dall'Era, M; Evans, CP; Gao, AC; Lara, PN; Liu, C; Pan, CX; Parikh, M; Robles, D; Wu, CY | 1 |
1 trial(s) available for abiraterone and niclosamide
| Article | Year |
|---|---|
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niclosamide; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2021 |
1 other study(ies) available for abiraterone and niclosamide
| Article | Year |
|---|---|
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Variation; Humans; Male; Mice, SCID; Niclosamide; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |